GlassScriptPhysician profile
Allison M Liddell
NPI 1831174069
$10,349.33
in general payments reported to CMS, 2019-2025
23 companies · $1,876 in 2025
The $1,876 reported for 2025 was more than what 85% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,225 · 2020: $782 · 2021: $1,630 · 2022: $1,641 · 2023: $1,872 · 2024: $1,324 · 2025: $1,876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,942 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,941.72 |
| Education | $129.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,667.54 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Merck Sharp & Dohme LLC | $1,118.86 | 2019-2025 | Pifeltro, Dificid, Delstrigo |
| Janssen Biotech, INC. | $985.79 | 2019-2023 | Symtuza |
| Abbvie INC. | $713.61 | 2021-2025 | |
| Gilead Sciences, INC. | $673.69 | 2019-2025 | Biktarvy |
| Paratek Pharmaceuticals, INC. | $637.05 | 2019-2025 | Nuzyra |
| Shionogi INC | $634.47 | 2021-2025 | Fetroja |
| Insmed, INC. | $601.96 | 2022-2025 | Arikayce, Brinsupri |
| Cumberland Pharmaceuticals, INC. | $439.70 | 2019-2025 | Vibativ |
| Melinta Therapeutics, LLC | $316.98 | 2022-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Theratechnologies INC. | $310.27 | 2019-2025 | Egrifta, Trogarzo |
| Ferring Pharmaceuticals INC. | $296.99 | 2023-2025 | Rebyota |
| Astellas Pharma US INC | $283.71 | 2019-2025 | Cresemba |
| Aimmune Therapeutics, INC. | $190.70 | 2024-2025 | Vowst |
| La Jolla Pharmaceutical Company | $132.55 | 2023-2025 | Xacduro, Zevtera, Xerava |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $86.02 | 2019-2022 | |
| Pfizer INC. | $62.51 | 2020-2025 | |
| Dynavax Technologies Corporation | $52.10 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $42.93 | 2022 | |
| Emd Serono, INC. | $33.05 | 2019 | |
| Janssen Products, LP | $29.99 | 2021 | |
| Seqirus USA INC | $26.11 | 2025 | Flucelvax, Fluad |
| Nabriva Therapeutics, Plc | $12.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Liddell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.